Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Subject has provided informed consent~* Chronic plaque psoriasis for at least 6 months prior to Screening~* PASI (Psoriasis Area and Severity Index) \>=12 and BSA (body surface area) \>=10% and IGA (Investigator's Global Assessment) score 3 or greater on a 5-point scale~* Candidates for systemic psoriasis therapy and/or phototherapy and/or chemophototherapy~* Female subjects must be postmenopausal, permanently sterilized or, if of childbearing potential, must be willing to use a highly effective method of contraception up till 20 weeks after last administration of study drug~* Male subjects with a partner of childbearing potential must be willing to use a condom when sexually active, up till 20 weeks after the last administration of study medication~Exclusion Criteria:~* Subjects with erythrodermic, guttate, pustular form of psoriasis, or drug-induced psoriasis~* Subject has any severe, progressive and/or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, gastrointestinal or neurological disease~* Subject has any significant concurrent medical condition or laboratory abnormalities, as defined in the study protocol~* Subject taking prohibited psoriatic medications~* Subject receiving any live vaccines within 8 weeks prior to the Baseline and subjects receiving Bacillus Calmette-Guerin (BCG) vaccination within 1 year prior to study drug administration~* Subject has previously received treatment with any anti-interleukin-17 (anti-IL-17) therapy or has been exposed to more than 1 biological response modifier (limited to anti-tumor necrosis factor (TNF) or IL-12/23) for psoriatic arthritis or psoriasis prior to the Baseline~* Subject has any current sign or symptom that may indicate an active infection (except for common cold)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Bimekizumab dosing regimen 1 (Type: EXPERIMENTAL): None
- Bimekizumab dosing regimen 2 (Type: EXPERIMENTAL): None
- Bimekizumab dosing regimen 3 (Type: EXPERIMENTAL): None
- Bimekizumab dosing regimen 4 (Type: EXPERIMENTAL): None
- Bimekizumab dosing regimen 5 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).